SMA Capital’s Travere Therapeutics TVTX Stock Holding History

SMA Capital’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-205	Closed	-$6.09K	–	168
2026 Q1	$6.09K	Buy	+205	New	+$6.13K	﹤0.01%	76

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SMA Capital's TVTX Position: Q2 2026 in Review

SMA Capital sold out of Travere Therapeutics (TVTX) in Q2 2026, closing a stake of 205 shares — an estimated $6.09K sold.

SMA Capital first reported a position in TVTX in Q1 2026 and held it in 1 quarter. The position peaked at $6.09K in Q1 2026. 319 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

SMA Capital reported no remaining Travere Therapeutics position as of Q2 2026 after selling out during the quarter.
SMA Capital sold 205 Travere Therapeutics shares in Q2 2026, an estimated $6.09K.
SMA Capital first reported a position in Travere Therapeutics in Q1 2026 and held it in 1 quarter.
SMA Capital's Travere Therapeutics position peaked at $6.09K in Q1 2026.
319 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on SMA Capital's 13F filing for Q2 2026, filed 14 Aug 2026.